Hormone receptor, grade, human epidermal growth factor receptor 2, and topoisomerase II as predictors of response to chemotherapy

Journal of Clinical Oncology

Volumn 26, Issue 15, 2008, Pages 2596-

  Mehta, Rita S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; PACLITAXEL; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DATA BASE; FOLLOW UP; HUMAN; LETTER; MULTIVARIATE ANALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; TREATMENT RESPONSE; CANCER STAGING; METABOLISM; NEOPLASM; NOTE; PATHOLOGY; PREDICTION AND FORECASTING;

ANTINEOPLASTIC AGENTS; DNA TOPOISOMERASES, TYPE II; HUMANS; NEOPLASM STAGING; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 45149115632     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.8724     Document Type: Letter

References (6)

1. Pritchard KI, Messersmith H, Elavathil L, et al: HER-2 and Topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26:736-744, 2008
2. Amat S, Penault-Llorca F, Cure H, et al: Scarff-Bloom-Richardson (SBR) grading: A pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 20:791-796, 2002
3. Bartlett JMS, Ellis IO, Dowsett M, et al: Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol 25:4423-4430, 2007
4. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006 [Erratum: JAMA 295:2356, 2006]
5. Sparano JA, Wang M, Martino S, et al: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671, 2008
6. Chen JH, Mehta RS, Carpenter PM, et al: Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy. J Clin Oncol 25:5667, 2007